Here's why the Imugene share price is plunging 15% today

The company's latest announcement has sent investors fleeing for the hills…

| More on:
A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares backtrack 15% to 18.7 cents
  • The company notified investors it has terminated a supply agreement with MSD for its immunotherapy HER-Vaxx
  • No reason was given for the termination

The Imugene Limited (ASX: IMU) share price is deep in the red today following a shock announcement from the company.

At the time of writing, the immuno-oncology company's shares are down 15% to 18.7 cents apiece.

It's worth noting that Imugene shares have extended their losses to around 23% in the past month.

Imugene terminates supply contract

Investors are selling off Imugene shares after the company advised it has cancelled a supply agreement with MSD. The latter is a tradename of pharmaceutical giant Merck & Co.

While no reason was given for the termination, Imugene is continuing with its clinical trial of HER-Vaxx.

The primary objective of the study is to determine the safety and efficacy of HER-Vaxx in combination with anti-PD-1 therapy.

The immunotherapy will be used for treatment of gastric, breast, ovarian, lung, and pancreatic cancers.

HER-Vaxx is a B-cell immunotherapy that has been shown in studies to "stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target".

PD1-Vaxx has the advantage that it induces a unique polyclonal immune response that may increase response rates for therapy.

Imugene share price snapshot

Despite today's fall, the Imugene share price has managed to remain 1.32% in the green over the past 12 months.

However, when looking year to date, its shares are down by 52%.

Imugene shares reached an all-time high of 62.5 cents in November, before shifting to a downhill trend.

Based on today's price, Imugene has a market capitalisation of roughly $1.12 billion with approximately 5.85 billion shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »